Pharmacokinetics of a novel surface-active agent, purified poloxamer 188, in rat, rabbit, dog and man.

Article Details

Citation

Grindel JM, Jaworski T, Emanuele RM, Culbreth P

Pharmacokinetics of a novel surface-active agent, purified poloxamer 188, in rat, rabbit, dog and man.

Biopharm Drug Dispos. 2002 Apr;23(3):87-103. doi: 10.1002/bdd.297.

PubMed ID
12173548 [ View in PubMed
]
Abstract

Purified poloxamer 188 (PP188) is a non-ionic, block copolymer surfactant that is currently being evaluated clinically in sickle cell disease vaso-occlusive crisis and acute chest syndrome and preclinically in spinal cord injury and muscular dystrophy. This paper describes the pharmacokinetics of PP188 in rats, pregnant rats, pregnant rabbits, dogs and humans. Plasma protein binding interaction studies demonstrated no clinically significant effects on narcotic analgesics, hydroxyurea, warfarin, diazepam or digitoxin, but an increase in free fraction for propranolol. The plasma concentrations increased proportionate with increasing dose in all species tested. Renal clearance accounted for 90% of total plasma clearance in man. A single metabolite was detected and quantified in the plasma from dogs and humans that was cleared more slowly than parent drug. Allometric scaling of plasma clearance and volume of distribution at steady-state (Vss) across species provided good predictions of the pharmacokinetic parameters in humans. Based on the comparative pharmacokinetics of PP188 in rat, rabbit, dog and man, all three animal species were appropriate models for evaluating various aspects of PP188's toxicological profile.

DrugBank Data that Cites this Article

Drugs